Try our Advanced Search for more refined results
Life Sciences - October, 2016
330 articles
- 2nd Circ. Urged Not To Revisit Pregnancy Test False-Ad Suit
- Judge Adds $21M To CardiAQ's $70M Trade Secrets Win
- Pfizer, Others Tell High Court PTAB Unfair To Patent Owners
- FDA Recommends Boxed Warning On Essure, Similar Devices
- Endo Says FTC Needs Permission To Pull Pay-For-Delay Suit
- U Of California Sues Boston Scientific Over AFib Devices
- Third Rock Closes Fourth Biotech Venture Fund At $616M
- SEC Says PwC Auditor Should Have Caught Fund Fraud
- EcoMed's $22M Contract Suit Sent To Mediation
- Stryker Can't Escape Hip Replacement Suit
- Prior Defects Could Sink Auvi-Q Even As EpiPen Prices Soar
- NJ Atty Urges 3rd Circ. To Rethink Frivolity Sanctions
- Justices Won't Hear Chemical Co.'s Infringement Appeal
- Generic Drug Co. Can't Kill Merck IP Suit Over Antifungal
- US Looks To Reinstate Charges In Meningitis Outbreak Suit
- 3rd Circ. Won't Rethink Provigil Antitrust Decision
- Adapt Or Die: Law Firms In Tomorrow's Economy — Part 2
- 3rd Circ. Weighs In On Product-Hopping
- When Your Client Is The President: Part 7
- Trial Bundling Comes Under Fire In Boston Scientific Appeal
- FDA OKs St. Jude Device For Lowering Certain Stroke Risks
- Is Talc The New Tobacco? $200M J&J Verdicts Show Potential
- PTAB Wins For Bass May Not Move Needle On Drug Prices
- Calif. Appeals Court Chops $13M Cooling Device Verdict
- FCA Decision Tracker: How Escobar Is Being Interpreted
- Promega Urges Justices To Back IP Meaning Of 'Substantial'
- CVS Settles Wage Statement Suit For $3M
- Don't 'Friend' Potential Jurors, IP Row Judge Warns Attys
- GSK Tells 3rd Circ. To End La. Case Over Settled Claims
- Misjoinder And Forum Shopping By The Government
- Judge Limits Zimmer Subpoenas To 'Shadow Organization'
- Unity Biotechnology Rakes In $116M From Investors
- Colgate, Tom's Face Suit Over 'Natural' Product Claims
- Astellas To Pay Up To $1.4B For German Cancer Drug Maker
- What Amici Say In High Court Patent Laches Case
- When Your Client Is The President: Part 6
- Adapt Or Die: Law Firms In Tomorrow's Economy — Part 1
- Rainmaker Q&A: Michael Best's Lisa Mueller
- Adderall Buyers Deride Objections To $15M Settlement
- J&J, Talc Co. Hit With $70M Baby Powder Cancer Verdict
- Challenge To Test Strip Injunction Falls Flat In 2nd Circ.
- Ex-Warner Chilcott Rep Gets Probation For HIPAA Violation
- Shkreli Wants To Bolster Defense With Katten Documents
- Endo Seeks Ruling On FTC Ability To Sue Over Past Conduct
- Kyle Bass Gets More Wins As PTAB Axes Celgene Patents
- GNC Tries To Throw Out 'Slack Fill' Protein Containers Suit
- University Of California Hits St. Jude With IP Suit
- Novartis, Amneal Settle Exelon Patch Infringement Fight
- Propel Orthodontics Ordered To Stop False Advertisements
- Antibody And Epitope Patent Prosecution Tips: Part 2
- When Your Client Is The President: Part 5
- Energy Drink Ad Claim Ruling Shows State Laws Matter
- China's New Social Credit System Presents Complications
- Labaton Secures $23.8M In Fees For Amgen Securities Deal
- USDA Scientist Cops To Lying About Seed-Stealing Plot
- Fed. Circ. Won't Lift Early Sales Ban In Qiagen Patent Case
- Generics Group Urges Justices To Hear Patent Locale Dispute
- Bowel Drug False Ad Suit Kept Alive
- Chicago Says Drug Cos.' Opioids Forced Spending On Addicts
- Neovasc Seeks Quick Win In Suit Over $70M Trial Loss
- Supplement Co. Says Foe Stealthily Selling Harmful Products
- 9th Circ. Revives Shareholder Suit Over Arena's Diet Drug
- VC-Backed Ra Pharmaceuticals Raises $92M In Upsized IPO
- Rainmaker Q&A: Orrick's Christina Guerola Sarchio
- Ex-Sanofi EpiPen Alternative Auvi-Q Coming Back In 2017
- Jury Hits Abbott Unit With $4.25M Age-Bias Verdict
- Bayer CEO Calls $66B Monsanto Tie-Up 'A Perfect Fit'
- Ex-Access CEO Must Repay $1.5M Kickbacks, 2nd Circ. Says
- Robbins Geller Made Lead Counsel In Insmed Stock Drop Suit
- FDA Moves Toward Online Database For Medical Device Info
- Antibody And Epitope Patent Prosecution Tips: Part 1
- When Your Client Is The President: Part 4
- InterMune Medical Chief Takes Stand Against Ex-Director
- St. Jude, Medtronic Sued Over Heart Valve Patents
- NJ Judge Sends Medical Device Co.'s Coverage Spat To Pa.
- J&J Asks Justices To End Circuit Split On Expert Misconduct
- Proctor & Gamble Get Last Fixodent Cases Axed
- Ex-Oppenheimer Adviser Cops To Insider Trading
- FDA Warning Wire: Device Deaths, Otsuka Woes, Teva Details
- FDA Unveils Site To Report Medical Device Violations
- Medicare Fraudster Gets 63 Months After 9th Circ. Win
- Nivea Maker Says No Evidence Showing Lotion Is A Drug
- Rainmaker Q&A: Greenberg Traurig's Richard Edlin
- How Pharma Cos. Can Shape The Drug-Pricing Landscape
- When Your Client Is The President: Part 3
- Bridging The Gap Between Outside And Inside Counsel
- Fla. Medical Marijuana Measure May Boost Business For Firms
- Bio-Rad Says Ex-GC Whistleblower Testimony Privileged
- CORRECTED: Pfizer Looks To Shake Damages Expert In Trade Secrets Trial
- InterMune Director Tipped Pal On Drug OK, SEC Tells Jury
- Kyle Bass Group Gets 1st Win As PTAB Nixes Gattex Claims
- Teva's Generic Overdose Drug Application Sparks IP Suit
- Listeria Prompts FDA Partial Hold On Cancer Drug Trial
- Abbott Whistleblower Urges 5th Circ. To Revive $219M Suit
- Researchers Claim No Defamation In St. Jude Security Report
- Zimmer Gets Quick Win In 2nd Knee Implant Defect Bellwether
- Recent Decisions Clarify Reach Of IPR Petitioner Estoppel
- When Your Client Is The President: Part 2
- So You Want To Be A Partner? You Need A Mentor
- Fla. Pharmacy Owner To Settle Tricare Fraud Charges For $4M
- Health Hires: Crowell & Moring, Goodwin, Faegre
- 6 Firms To Steer 7 IPOs Totaling $2.6B Led By Blockbuster
- Canadian Justices Urged To Nix 'Promise Doctrine' In IP Row
- McDermott Gains Transactional Partner From Locke Lord
- Medical Co. Never Bought Duty To Defend, Insurer Says
- Drugmaker Takes Flanax Trademark Case To Supreme Court
- Court Shows No Love for Aphrodisiac Class Certification
- Vitamin Buyers Seek Class Cert. In 'Made In USA' Suit
- When Your Client Is The President: Part 1
- J&J Talcum Powder Users Dying Of Ovarian Cancer, Atty Says
- High Court Denies Consumers Cert. In P&G Fixodent MDL
- CVS To Pay $600,000 To Settle Controlled Substance Claims
- Judge Aghast At Iowa Brothers' Defiance In NuScience IP Row
- Judge Splits FTC's Endo Case, Scoffs At Transfer Threat
- Pot Fertilizer Co. Says Denver Weed Chain Threatened TM Suit
- GSK, Teva Urge High Court To Review Pay-For-Delay Accords
- Pipe Maker, Biotech Price IPOs Raising $439M
- Merck Tells Justices Only Public Sales Trigger On-Sale Bar
- Judge Defends Jury But Carves $2M From Mesh Verdict
- Ex-NJ Prosecutor Joins Epstein Becker's Health Group
- Fed. Circ. Says It Can't Review PTAB Decision To Ax Review
- FTC, Antitrust Org Ask 3rd Circ. To Rethink Doryx Decision
- Trial Pros' Secret To Courtroom Success
- Prosecuted For Truthful Off-Label Promotion: Part 2
- Whistleblower Drops Multimillion-Dollar Lincare FCA Suit
- Supplement Maker Sued Over Dubious HGH-Boosting Claims
- Are Your Witnesses Watered Down?
- Align Stock Losses Were Fraud, Not Bad Biz, 9th Circ. Told
- Judge Refuses To Nix Depakote Birth-Defect Suit In Ill.
- USPTO Wins Dispute Over Extension For Drug Patent
- US Says Smoking Materials Importer Owes $193K In Penalties
- Legal, Biz Groups Back Pfizer In 3rd Circ. Birth Defect Row
- Theranos' Woes May Reshape Private D&O Coverage
- Relator Pulls State Insurance Fraud Claim Against Medtronic
- Supreme Court Urged To End Laches Defense In Patent Cases
- Prosecuted For Truthful Off-Label Promotion: Part 1
- Gilead Says Ferring Win Should Extend HIV Drug Exclusivity
- Biotech IPO, Two Follow-On Offerings Top $350M
- Syngenta Says Kansas Class Can't Join Trial In GMO MDL
- Boehringer Offers EU Concessions For Sanofi Swap Deal
- Talking 'Bull': Episode 4, Callisto
- Boston Scientific Urges High Court To Nix $308M IP Verdict
- St. Jude Forms Medical Device Cybersecurity Board
- GE Cites IP Atty Breach In Barnes & Thornburg DQ Motion
- Fed. Circ. Backs Nix Of GSK Flu Inhaler Patent Application
- 2nd Circ. Pushes Back As Ex-CEO Appeals Kickback Liability
- GSK Can't Seek To Deflect Blame, Reed Smith Widow Says
- FDA Warning Wire: Teva Factory Woes, Camel Milk Claims
- 7th Circ. Backs Teva In Atty's Breast Cancer Suit
- No More Vaginal Mesh Suits, MDL Judge Says
- Abbott, St. Jude Ink $1B Deal To Shed Product Portfolio
- Legal Battle Over 100-Year-Old Drug Previews Big Price Hike
- Advil 'Slack-Fill' Claims Come Up Empty, Judge Finds
- Fera Taking Loss Over Thyroid Drug Generic To Fed. Circ.
- Sanofi Seeks Early Win, Defeat Of Class Cert. In TCPA Suit
- Ysios Capital Closes $139M Euro Biotech, Health Care Fund
- Quark, GF Securities Launch $500M Health Sciences Fund
- Bayer-Monsanto Won't Seed Or Weed The Patent Thicket
- Pfizer To Launch Biosimilar Of J&J's Top-Selling Remicade
- Mylan Sued By EpiPen Buyers Over Pricing, Marketing Tactics
- Cook Medical's 2nd Bellwether Pick OK'd In Vein Filter MDL
- FDA Places Hold On Regeneron-Teva Pain Drug Study
- MoFo Nabs WilmerHale Drug IP Partner And Ex-Gilead Atty
- Provigil Pay-For-Delay Suit Belongs In Pa., Teva Says
- Hyland's To Pay Refunds, $2.9M In Fees To End False Ad Row
- Monsanto Hit With False Ad Suit Over Roundup Concentrate
- PE-Backed Acushnet Tops 5 IPO Launches Totaling $907M
- Hyland's Resists Consumer's Bid For New False Ad Trial
- Pot Zoning Rule Needs No Enviro Review, Calif. Court Says
- Mylan's $465M EpiPen Deal With DOJ Too Lenient, Sen. Says
- 3rd Circ. Got Doryx Product-Hopping Suit Wrong, Mylan Says
- Actavis Holdco Says FTC's AndroGel Antitrust Suit Is Moot
- OPINION: 3rd-Party Litigation Funding Needs Transparency
- Another Champion For Proportionality In MDL Discovery
- Omnicare Pays $28M In Depakote Kickbacks Case
- Rainmaker Q&A: Goodwin Procter's Stuart Cable
- Feds Blast Shkreli's Ex-Atty's Bid For Conspiracy Details
- Cosmetics Co. To Pay $5.6M To End Suit Over Bungled Merger
- Pfizer Settles Long-Running Cancer Research IP Suit
- Bristol-Myers Wants High Court Review Of Calif. Jurisdiction
- 3 Firms To Lead IPOs Totaling $518M As Deals Begin To Slow
- Health Hires: Greensfelder, Cozen O'Connor, Goodwin
- Infection Risk In LivaNova's Blood Temp. Device, CDC Warns
- Pfizer Unit To Pay Feds Extra $230K For NJ Pollution
- Evidence Doesn't Back $70M Pa. Risperdal Award, J&J Says
- Fed. Circ. Affirms Gilstrap's Validation Of Endo Patents
- Maynard Cooper Opens NY Office With 3 IP Partners
- Obama Opens Door To Pharma Trade With Cuba
- Law Firm Seeks To Avoid Indemnifying For GSK Settlement
- Sex Pill Claims Too Vague To Be Misleading, Judge Rules
- Drug Plaintiffs Can't Avoid Learned Intermediaries
- GSK Wants Fraud Claims Dismissed In Zofran MDL
- Pradaxa Warnings Were Adequate, Boehringer Ingelheim Says
- Boston Scientific Wants 4 New Trials After $27M Verdict
- Supplement Cos. Seek Fees From 'Patent Troll' ThermoLife
- Fed. Circ. Backs MIT In Cell-Growing Mesh Patent Case
- NJ Time Limits Should Apply To Accutane Case, Justices Told
- Astellas Targets Generic Versions Of Bladder Drug Myrbetriq
- A Gift By Any Other Name: Benefits In McDonnell And Salman
- Escobar Supports Nixing $40B FCA Suit, Celgene Says
- Sandoz, Taro, Others Hit With Antitrust Suit Over Skin Cream
- NJ Accutane Litigation Trimmed By 160 Suits
- Life Alert To Pay $3.2M To End Workers' FLSA Suit
- Pfizer Asks 3rd Circ. To Uphold Its Win In Birth Defect MDL
- Calif. Life Sciences Cos. Sued Over Sale Of Fetal Tissue
- Allergan, Others Fight Eye Drop Class Cert. At 7th Circ.
- Theranos, Walgreen Blood-Test Suits Consolidated In Ariz.
- 5th Circ. Tells Widow Vioxx Deal Protects Seeger Weiss
- J&J Trial's Remote Witnesses Test Limits Of Subpoena Power
- Allergan Investors Urge Class Cert. In Insider Trading Row
- 10 Baby Deaths Possibly Tied To Teething Products, FDA Says
- Whistleblowers Revive Novartis Xolair Kickback Suit In NY
- Extraction Oil & Gas Tops 3 IPOs Totaling $700M
- Treasury's Inversion Rule Undermines Tax Law, Chamber Says
- Ice Cream And Talking Pictures: Brandeis On Patents
- 3rd Circ. Upholds Zimmer Win In Replacement Hip Suit
- Actavis Looks To Flip 'Pill Mill' Coverage Loss On Appeal
- Warner Chilcott Wants Claims Cut In Generic-Blocking Suit
- The Art Of Silence At Trial
- Besin Denied Quick Exit In Testosterone Replacement MDL
- Similar NY Case Moots Del. Derivative Suit, BioScrip Says
- FDA Says Faulty Device Didn't Affect Xarelto Trial Results
- Justices Won't Hear Merck Challenge Of AIA Appeal Standard
- FDA Warning Wire: Pistachios Linked To Salmonella Outbreak
- Army Accused Of Price Bamboozle In $40M Staffing Contract
- Ex-Warner Chilcott Manager Gets Probation For Fraud
- Fund Sues Theranos Over Stock Purchase Agreement
- Celladon Ditches Investor Suit Over Mydicar Trial Claims
- Sorin Can't Dodge Contaminated Hospital Equipment Suit
- St. Jude Warns Of Early Battery Depletion In Cardiac Devices
- E-Cig Makers Grilled On Challenge To FDA Rules
- Biotech Zymergen Banks $130M From Private Investors
- Highlights Of The FDA's Abbreviated New Drug Applications
- Mylan's EpiPen Rebate Errors Spark SEC Probe, Investor Suit
- Pfizer Wants Out Of Suit Over Pain Patch Marketing
- Patents For Computer Applications, Not Medical Diagnostics?
- 10 Things To Look For This Supreme Court Term
- Chancery Slashes Fee Request Fourfold In Cryo-Cell Case
- Taxation With Representation: Skadden, Latham, Kirkland
- Teva, Amneal Lose Opana ER Patent Fight Against Endo
- 23andMe Arbitration Order Refused Rehearing By 9th Circ.
- Mylan Inks $465M Deal Over EpiPen Rebates
- Don't Toss Meningitis MDL Cases On Technicality, Judge Told
- Roxane Asks Fed. Circ. To Halt Hetero's Generic Kidney Drug
- Sheller Spat Over FDA Risperdal Petition Denial Axed
- EPA, Chem Maker Settle Wash. Reservation Air Pollution Row
- Orange County DA Sues Over Niaspan Pay-For-Delay Scheme
- Nivea Skin-Firming Lotion An Unapproved Drug, Suit Says
- NY Health Dept. Wrongly Denying Speech Aids, Suit Says
- Kyle Bass Loses Challenge To Shire's Lialda Patent At PTAB
- Familes Blast GSK's New Zofran Label Submission In MDL
- J&J Attacks Cosmetics Expert In Baby Powder Cancer Trial
- DOJ Pummels Medical Supplier's Kickback Defenses
- FDA Issues New Rules For Pharmaceutical Patent Litigation
- Lamictal Pay-For-Delay Case Not Best High Court Lure
- ICU Medical Inks $1B Deal For Pfizer Infusion Therapy Unit
- Pfizer Wins Dismissal Of Zoloft Developmental Delay Suit
- McDermott Will Adds Silicon Valley M&A Partner From MoFo
- Coming Soon: The 3-D (And 4-D) Brief
- NJ Lawmakers Advance EpiPen Affordability Bill
- Fed. Circ. Judge Puzzled By USPTO Stance In Settled IP Row
- Health Care M&A Fades After Year In The Spotlight
- BTG Announces $36M Settlement Of DOJ Marketing Probe
- J&J Demands Mistrial As DePuy Chief Takes Stand
- Theranos Closing Labs, Slashing Staff Amid Legal Troubles
- J&J Should Have Warned Of Talc Risks Since 1982, Jury Told
- J&J Mea Culpa May Help Contain Device Data Security Fallout
- UnitedHealth Gouged Patients On Drug Prices, Suit Says
- Buyers Ask 1st Circ. For Nexium Antitrust Case Redo
- Parents Slam Bid To Toss GSK Zofran Suit From MDL
- FDA Must Block Virtus' Shoddy Meds, Drugmaker Says
- Minn. High Court Hears Medtronic Investor's Inversion Case
- Gov't EpiPen Spending Increased Nearly 500%, CMS Says
- Taxotere-Related Hair Loss Suits Centralized In Louisiana
- Pfizer Wields Ferring Win To Extend Combo Drug Exclusivity
- Teva Inks $769M Deal To Sell Allergan Assets In UK, Ireland
- Novartis Pays $35M To End Elidel Off-Label Marketing Suit
- 3rd Circ. Refuses To Revive Novartis Labeling Suit
- Worker's OT Class Claims Revived In Arbitration Dispute
- Boehringer Sheds US Pet Vaccines In $885M Elanco Deal
- Seyfarth Shaw Adds IP Boutique Fanelli Haag In DC
- 2nd Circ. Asked To Rethink Vitamin C Antitrust Class Action
- J&J Baby Powder Cancer MDL Centralized In NJ
- What To Expect From A Congressional Investigation
- US Asks High Court Not To Take Lamictal Pay-For-Delay Row
- The 'Tough Noogies' Doctrine: Rights But No Remedies
- Another Slam Dunk Infuse Win — Preemption and More
- Baxter Gets Medical Device Lawsuit Chopped In Half
- J&J Says Insulin Device Can Be Hacked But Risk Is Low
- TWi Awarded $12.7M In Bonds In Appetite Drug Patent Suit
- Aveeno Buyers Get Class Cert. In 'Natural' Labeling Suit
- J&J Attacks Alternative Artificial Hip During First Cross
- J&J Unit Challenges PTAB Institutions At High Court
- Procter & Gamble Renews Quick Win Bid In Fixodent MDL
- P&G Beats Old Spice Chemical Burn, Skin Rash Suit For Now
- J&J Hid Talc Baby Powder Cancer Risks, Jury Told
- FDA Warns That Hep C Meds Can Reactivate Hep B
- Pharmacists Duck Criminal Charges Over Meningitis Outbreak
- JPML Consolidates Abilify Gambling Suits In Florida
- Rainmaker Q&A: Deans & Lyons' Chad Castille
- Congress Clear About AIA's On-Sale Bar, Patent Office Says
- Enzo Hits Hologic With Suit Over DNA Patent
- Clarion Drops $311M On Mass. Life Sciences Complex
- Allergan Loses Bid For 3rd Circ. Rehearing Of Eye Drop Suit
- AdvoCare Wants To Arbitrate Ex-Director's Claim To CEO Spot
- FTC Warns Against Endo Privilege Request In Lidoderm MDL
- 3rd Circ. Confirms Free Assignability Of Antitrust Claims
- A Look At Manufacturer Liability For The Internet Of Things
- Bristol-Meyers May Slash Non-Californians From Ongylza Row
- J&J Artificial Hips' Market Success Built On Lies, Jury Told
- Customer Fights To Keep Sex Pill Suit From Being Rejected
- Boston Scientific Can't Escape $14.3M Mesh Defect Verdict
- Vitamin Maker Says 'Made In USA' Labeling Suit Is 'Cribbed'
- Justices Won't Eye Reach Of Hatch-Waxman Safe Harbor
- No End To IPO Flurry As 4 More Firms Reveal Plans
- 1st Circ. Won't Revive Suit Over Vertex Stock Drop
- Feds Say Shkreli, Ex-Atty Have Enough Info On Fraud Case
- High Court Won't Hear RICO Causation Suit Over Sanofi Drug
- Deals Rumor Mill: Royal Philips, Bai Brands, Concordia
- Justices Won't Hear Ruling That Mayo Dooms Genetic Patent
- Puma Investors' Suit Lives As Judge Dings Judicial Notice
- 3rd Circ. Denies Rehearing Of Claims-Aggregation Ruling
- Drug Cos. Deride FTC's Lidoderm, Opana Antitrust Suit
- Justices Reject Bias Dispute Over Arbitrator's BigLaw Brother
- Justices Won't Review FCA Disclosure, Pleading Concerns
- Private Investors Plug $95M Into New European Oncology Firm
- Aegerion Investor Says CEO Job Offer 'Taints' $43M Deal
- Texas Firm Will Pay $350K To Exit Fee Row Over Bayer MDL
- PE-Backed Medical Tech Firm Seeks $1.8B In London IPO
- Rainmaker Q&A: Nixon Peabody's Jill Gordon